Report Library
All ReportsDrug Pricing and Market Access KOL Interview
February 01, 2016
If you are a KOL Insight Subscriber, please access this report here, in our KOL
Insight portal (Subscribers only).
Highlights
For our disclosures, please read the BioMedTracker Research Standards.
Highlights
- Expensive oncology treatments [PD-1 and upcoming CAR-T therapies] will continue to be covered by large insurers formularies, but access will be restricted according to NCCN guidelines.
- Sustainability of healthcare costs is a big question and will be largely dependent on government actions as with recent turn from fee for service to episode of care.
- Very large insurers care about long-term cost-savings of curative treatments, but most commercial plans are only looking a year down the road.
- PCSK9 drugs may be a coverage concern if in statin failure indication, but coverage would likely be highly managed.
- The methodology of this large insurer will not change substantially in response to the lessons learned from Hepatitis C drugs.
For our disclosures, please read the BioMedTracker Research Standards.
Disease Group Covered: |
Cardiovascular
Oncology |
Indications Covered: | Castleman's Disease |
Additional Resources: